Long-Acting HIV Injections Set to Transform Treatment Landscape
Table of Contents
- Long-Acting HIV Injections Set to Transform Treatment Landscape
- Long-Acting HIV Injections: Your Questions Answered
- WhatS the big news about HIV treatment?
- How can these injections improve the quality of life for people with HIV?
- What are some of the available long-acting HIV injection options?
- Tell me more about Bocabria+Lechamvis.
- What is GSK doing to improve Bocabria+Lechamvis?
- What about Gilead Sciences and their long-acting HIV options?
- How effective are these preventative injections?
- how has HIV treatment evolved over time?
- What impact are these new long-acting drugs expected to have on the market?
- Here’s a simple comparison of the two main long-acting HIV treatments mentioned:
Effective April 1, long-term injectable treatments for HIV are slated to be covered under health insurance, potentially shifting the focus of HIV management from daily pills to less frequent injections. This change could considerably improve the quality of life for individuals living with HIV.
Bocabria+Lechamvis: A Bi-Monthly Option
The bi-monthly injection, Bocabria+Lechamvis, received Food and Drug Governance approval in 2022. GlaxoSmithKline (GSK), a British pharmaceutical company, is managing the domestic insurance registration in conjunction with Johnson & Johnson (J&J) of the United States. This marks the first long-acting HIV treatment option available in Korea.
From ‘Death Sentence’ to Chronic Management
The first cases of AIDS, caused by HIV, were reported in the U.S. in 1981. Initially, with no effective treatments, HIV and AIDS were considered a death sentence. Though, advancements in drug technology have transformed HIV into a manageable chronic condition. Early diagnosis and consistent medication allow individuals with HIV to live near-normal lifespans.
GSK Trials Aim for Extended Injection Intervals
GSK is currently conducting clinical trials to explore extending the interval between Bocabria injections, potentially offering even less frequent dosing. These trials also include preventative measures, administering the injection to high-risk groups to prevent HIV infection and the progression to AIDS.
Gilead sciences and the Annual Injection
Gilead Sciences, another major player in antiviral medications, launched Sunlenka in 2022 in the United States, administered twice a year. Yuhan Chemical, a subsidiary of Yuhan Corporation, handles the drug supply. Gilead is also developing a once-yearly preventative injection. Clinical trials have demonstrated a 96% reduction in HIV infection rates with this approach in studies conducted in thailand and the United States.
Market Growth and paradigm Shift
An industry official noted the challenges of daily medication adherence, stating that the visibility of taking daily pills could inadvertently expose an individual’s HIV status. The growth of these new long-acting drugs is expected to fuel growth in the HIV treatment market.The global market, valued at 47 trillion won in 2023, is projected to reach 65 trillion won by 2032.The domestic market was valued at 120 billion won last year.
Long-Acting HIV Injections: Your Questions Answered
WhatS the big news about HIV treatment?
Long-acting injectable treatments for HIV are becoming more accessible! Effective April 1st, these treatments will be covered under health insurance, shifting the focus from daily pills to less frequent injections. this change coudl substantially improve the quality of life for people living with HIV.
How can these injections improve the quality of life for people with HIV?
The move from daily pills to less frequent injections offers multiple advantages. It reduces the burden of remembering to take medication every day, which can be a meaningful challenge. The visibility of taking daily pills can,unfortunately,inadvertently expose an individual’s HIV status; injections offer more discretion.
What are some of the available long-acting HIV injection options?
The article mentions two main options:
bocabria+Lechamvis: This is a bi-monthly injection.
Sunlenka: This injection, available in the United states, is given twice a year. A once-yearly preventative injection is also in development.
Tell me more about Bocabria+Lechamvis.
Bocabria+Lechamvis is a bi-monthly injection. It received Food and Drug Governance approval in 2022. GlaxoSmithKline (GSK), a British pharmaceutical company, is managing its domestic insurance registration in partnership with Johnson & Johnson (J&J) of the United States. This makes it the first long-acting HIV treatment option available in Korea.
What is GSK doing to improve Bocabria+Lechamvis?
GSK is currently conducting clinical trials to see if they can extend the interval between Bocabria injections, perhaps offering even less frequent dosing. These trials also explore preventative measures, administering the injection to high-risk groups to prevent HIV infection and the progression to AIDS.
What about Gilead Sciences and their long-acting HIV options?
Gilead Sciences launched Sunlenka in 2022 in the United States, which is administered twice a year. Yuhan Chemical, a subsidiary of Yuhan Corporation, handles the drug supply. Moreover, gilead is developing a once-yearly preventative injection.
How effective are these preventative injections?
Clinical trials have shown a 96% reduction in HIV infection rates with the once-yearly approach. These studies were conducted in Thailand and the United States.
how has HIV treatment evolved over time?
In the early 1980s, when HIV and AIDS first appeared, there were no effective treatments and it was considered a death sentence. Thanks to significant advancements in drug technology, HIV is now a manageable chronic condition. Early diagnosis and consistent medication allow people with HIV to live near-normal lifespans.
What impact are these new long-acting drugs expected to have on the market?
The growth of long-acting drugs is expected to fuel the growth of the HIV treatment market. The global HIV treatment market, valued at 47 trillion won in 2023, is projected to reach 65 trillion won by 2032. The domestic market was valued at 120 billion won last year.
Here’s a simple comparison of the two main long-acting HIV treatments mentioned:
| Treatment | Administration Frequency | Company | Status/Location |
|---|---|---|---|
| Bocabria+Lechamvis | Bi-monthly | GlaxoSmithKline (GSK) | Available in Korea (insurance coverage starting april 1st) |
| Sunlenka | Twice a year | Gilead Sciences | Available in the United States. |
